Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in ReceivablesChange in TaxesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Altimmune (ALT) Gains from Investment Securities (2016 - 2025)

Altimmune (ALT) has disclosed Gains from Investment Securities for 13 consecutive years, with $42679.0 as the latest value for Q1 2025.

  • On a quarterly basis, Gains from Investment Securities fell 92.89% to $42679.0 in Q1 2025 year-over-year; TTM through Sep 2025 was $606000.0, a 0.0% change, with the full-year FY2024 number at $6.6 million, up 31.46% from a year prior.
  • Gains from Investment Securities was $42679.0 for Q1 2025 at Altimmune, down from $6.6 million in the prior quarter.
  • In the past five years, Gains from Investment Securities ranged from a high of $6.6 million in Q4 2024 to a low of -$1.8 million in Q1 2022.
  • A 5-year average of $1.8 million and a median of $740000.0 in 2021 define the central range for Gains from Investment Securities.
  • Biggest YoY gain for Gains from Investment Securities was 22302.09% in 2022; the steepest drop was 302.27% in 2022.
  • Altimmune's Gains from Investment Securities stood at -$860000.0 in 2021, then soared by 493.48% to $3.4 million in 2022, then surged by 49.05% to $5.0 million in 2023, then surged by 31.46% to $6.6 million in 2024, then plummeted by 99.36% to $42679.0 in 2025.
  • Per Business Quant, the three most recent readings for ALT's Gains from Investment Securities are $42679.0 (Q1 2025), $6.6 million (Q4 2024), and $4000.0 (Q3 2024).